Navigation Links
Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Date:10/1/2007

- Multi-Center Phase 1 Trial to Commence -

CARLSBAD, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Pink Sheets: ARDC), a company focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) granted safe-to-proceed status to the Investigational New Drug (IND) application for RDEA119, enabling initiation of a Phase 1 clinical trial in advanced cancer patients. RDEA119 is a highly potent and selective inhibitor of mitogen-activated ERK kinase (MEK), a key component of the RAS/RAF/MEK/ERK pathway that is commonly defective in human tumors.

Ardea Biosciences plans to conduct the Phase 1 clinical trial at several academic medical centers in the United States. The open-label, dose-escalation trial is designed to evaluate the safety, tolerability and pharmacokinetics of RDEA119 following oral administration in patients with advanced cancer. In addition, the trial is designed to examine biomarkers of therapeutic activity in these patients.

"Cancer is the second most common cause of death in the United States, and, although progress is being made, there is still a significant unmet medical need. The FDA's clearance for us to proceed with our Phase 1 study is a key step forward in the development path for RDEA119, as well as our MEK inhibitor program in general," said Barry Quart, PharmD, President and CEO.

"In clinical trials, MEK inhibitors have been shown to have activity in patients with certain kinds of cancers. With its selectivity, potency and limited penetration into the brain, RDEA119 appears to have a very favorable profile. We are very excited to be selected to participate in the Phase 1 program for this interesting molecule," said Dan Von Hoff, MD, Physician in Chief, Translational Genomics Research Institute and Chief Scientific Officer, Scottsdale Healthc
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 Quietly, sedately, ... experience, the domestic pharmaceutical industry is strong, with a ... to high international standards. One place where ... in sub-Saharan Africa: Morocco has quietly become the second ... South Africa . Indeed, Moroccan pharma companies have ...
(Date:7/31/2015)... Inc. (Nasdaq: SMLR ), a company that provides ... groups, today reported financial results for the second quarter ... second quarter of 2015, Semler reported continued progress with ... quarter revenue growth of 8%, and quarter over quarter ... 18%," said Doug Murphy-Chutorian, M.D., chief executive officer of ...
(Date:7/31/2015)... MONROVIA, Calif. , July 31, 2015  Xencor, ... developing engineered monoclonal antibodies for the treatment of autoimmune ... the appointment of Yujiro S. Hata to ... of experience in business and corporate development is a ... , Ph.D., president and chief executive officer of Xencor. ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their flagship ... at the 2015 Vans US Open of Surfing, July 25 through August 2 in ... added sugar” on the market, is a natural choice given the Open’s commitment to ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down ... . Those looking to catch a new and refreshing show on Broadway, look ... awards and achievements including an Obie Award, Outer Critics Circle Award, Drama Desk Award, ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... According ... and cosmetic experts gathered to see if they could reach a consensus on the ... breast augmentation and facelifts. Overall, the group reached 90 percent consensus on a series ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... lecture on pharmaceutical negligence is now available online at ( http://www.lawline.com/cle/course/its-a-wonderful-life-if-you-receive-the-right-meds-a-discussion-of-pharmaceutical-negligence ). ... a 94% approval rating from the nationwide audience. The course focused ...
(Date:7/31/2015)... ... July 31, 2015 , ... As part of their company mission, Dallas ... animal welfare organizations is essential to the longevity of their business. It is ... Association of Professional Pet Sitters (NAPPS) annual Presents 4 Pets supply drive. ...
Breaking Medicine News(10 mins):Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4
... new study conducted by investigators at Harvard Medical ... S-Adenosyl Methionine (SAMe), an over-the-counter dietary supplement, can ... adults with major depressive disorders who do not ... This first-of-its-kind study was published in the August ...
... landmark international study, coordinated by McMaster University, has ... called unfractionated heparin (UFH) during angioplasty did not ... dose UFH in patients initially treated with a ... the OASIS 5 trial, researchers from McMaster University ...
... of ten workers 85 percent rate workplace safety ... and maternity leave, minimum wage, paid sick days, overtime pay ... new study from the National Opinion Research Center at the ... and Experiences with Workplace Safety," draws on dozens of surveys ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... as marijuana, reduced pain in patients with nerve pain ... Twenty-one adults with chronic nerve pain were taught ... cannabis through a pipe, three times a day, for ...
... young women during visits to family planning clinics whether ... pregnant a type of intimate-partner violence called reproductive ... would continue to experience such pressures, according to a ... Davis School of Medicine. Young women who recently ...
... release is available in French . The ... legislators and the public at large for many years as ... not always be effective and may have unwanted side effects. ... McGill University researchers provides evidence that cannabis may offer relief ...
Cached Medicine News:Health News:Study findings show value of dietary supplement SAMe in treatment of adults with major depressive disorders 2Health News:Study findings show value of dietary supplement SAMe in treatment of adults with major depressive disorders 3Health News:Drug trial results refine treatment during angioplasty operations 2Health News:Drug trial results refine treatment during angioplasty operations 3Health News:Workers rate safety most important workplace issue in new Labor Day study 2Health News:Smoked Marijuana May Ease Chronic Nerve Pain 2Health News:Smoked Marijuana May Ease Chronic Nerve Pain 3Health News:Study finds asking about pregnancy coercion and intimate-partner violence can reduce their incidence 2Health News:Study finds asking about pregnancy coercion and intimate-partner violence can reduce their incidence 3Health News:Research demonstrates benefits of medical cannabis as a treatment for chronic pain 2
Multispot HIV-1/HIV-2 is a rapid indirect EIA using recombinant and peptide antigens for simultaneous detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies in human serum or plasma....
Mini Aprons are half aprons with an easy-on, easy-off Velcro-style closure that fastens securely in seconds. Color-coded sizes for easy identification. Offers 0.5 mm Pb equivalent protection....
... the first in portability and performance. CTU is ... a flexible, portable system with the state-of-the-art features of ... to an "E" size tank and has an optional ... it is needed.,The CTU Travel Case allows you to ...
Pilot and control your analysis at a touch. 26 parameters CBC/DIFF with autoloader...
Medicine Products: